Steven Brem

Dr. Steven Brem

Department of Neurosurgery, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
DODonald M. O’rourke
Donald M. O’rourke
MNMacLean Pancoast Nasrallah
MacLean Pancoast Nasrallah
ADArati Desai
Arati Desai
Jan Joseph MelenhorstJan Joseph Melenhorst
Jan Joseph Melenhorst
KMKeith Mansfield
Keith Mansfield
MMMarcela V. Maus
Marcela V. Maus
A trial of autologous T cells redirected to a specific mutation in glioblastoma patients illustrates mechanisms of resistance.

29 July 2022 in Scientific Data
Verified
Journal Article
Open access
PDF file
Spyridon BakasSpyridon Bakas
Spyridon Bakas
CSChiharu Sako
Chiharu Sako
HAHamed Akbari
Hamed Akbari
MBMichel Bilello
Michel Bilello
ASAristeidis Sotiras
Aristeidis Sotiras
CDChristos Davatzikos
Christos Davatzikos
Glioblastoma is the most common aggressive adult brain tumor. Numerous studies have reported results from either private institutional data or publicly available datasets. However, current public datasets are limited in terms of: a) number of subjects, b) lack of consistent acquisition protocol, c) data quality, or d) accompanying clinical, demographic, and molecular information. Toward alleviating these limitations, we contribute the “University of Pennsylvania Glioblastoma Imaging, Genomics, and Radiomics” (UPenn-GBM) dataset, which describes the currently largest publicly available comprehensive collection of 630 patients diagnosed withde novoglioblastoma. The UPenn-GBM dataset includes (a) advanced multi-parametric magnetic resonance imaging scans acquired during routine clinical practice, at the University of Pennsylvania Health System, (b) accompanying clinical, demographic, and molecular information, (d) perfusion and diffusion derivative volumes, (e) computationally-derived and manually-revised expert annotations of tumor sub-regions, as well as (f) quantitative imaging (also known as radiomic) features corresponding to each of these regions. This collection describes our contribution towards repeatable, reproducible, and comparative quantitative studies leading to new predictive, prognostic, and diagnostic assessments.

12 January 2024 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
SBStephen Joseph Bagley
Stephen Joseph Bagley
ZBZev A. Binder
Zev A. Binder
LLLamia Lamrani
Lamia Lamrani
EMEliana Marinari
Eliana Marinari
ADArati S. Desai
Arati S. Desai
DODonald M. O’rOurke
Donald M. O’rOurke

1 February 2020 in Neurosurgical Focus
Verified
Journal Article
Open access
PDF file
FHFraser Henderson
Fraser Henderson
KAKalil G. Abdullah
Kalil G. Abdullah
RVRagini Verma
Ragini Verma
Steven BremSteven Brem
Steven Brem
The ability of diffusion tensor MRI to detect the preferential diffusion of water in cerebral white matter tracts enables neurosurgeons to noninvasively visualize the relationship of lesions to functional neural pathways. Although viewed as a research tool in its infancy, diffusion tractography has evolved into a neurosurgical tool with applications in glioma surgery that are enhanced by evolutions in crossing fiber visualization, edema correction, and automated tract identification. In this paper the current literature supporting the use of tractography in brain tumor surgery is summarized, highlighting important clinical studies on the application of diffusion tensor imaging (DTI) for preoperative planning of glioma resection, and risk assessment to analyze postoperative outcomes. The key methods of tractography in current practice and crucial white matter fiber bundles are summarized. After a review of the physical basis of DTI and post-DTI tractography, the authors discuss the methodologies with which to adapt DT image processing for surgical planning, as well as the potential of connectomic imaging to facilitate a network approach to oncofunctional optimization in glioma surgery.

26 February 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MHMenggui Huang
Menggui Huang
Duo ZhangDuo Zhang
Duo Zhang
JWJanet Wu
Janet Wu
KXKun Xing
Kun Xing
EYEujin Yeo
Eujin Yeo
YFYi Fan
Yi Fan
Therapeutic resistance remains a persistent challenge for patients with malignant tumors. Here, we reveal that endothelial cells (ECs) acquire transformation into mesenchymal stem cell (MSC)–like cells in glioblastoma (GBM), driving tumor resistance to cytotoxic treatment. Transcriptome analysis by RNA sequencing (RNA-seq) revealed that ECs undergo mesenchymal transformation and stemness-like activation in GBM microenvironment. Furthermore, we identified a c-Met–mediated axis that induces β-catenin phosphorylation at Ser675 and Wnt signaling activation, inducing multidrug resistance–associated protein-1(MRP-1) expression and leading to EC stemness-like activation and chemoresistance. Last, genetic ablation of β-catenin in ECs overcome GBM tumor resistance to temozolomide (TMZ) chemotherapy in vivo. Combination of Wnt inhibition and TMZ chemotherapy eliminated tumor-associated ECs, inhibited GBM growth, and increased mouse survival. These findings identified a cell plasticity–based, microenvironment-dependent mechanism that controls tumor chemoresistance, and suggest that targeting Wnt/β-catenin–mediated EC transformation and stemness activation may overcome therapeutic resistance in GBM.

16 April 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
BEBenjamin M. Ellingson
Benjamin M. Ellingson
JSJohn Sampson
John Sampson
AAAchal Singh Achrol
Achal Singh Achrol
MAManish K. Aghi
Manish K. Aghi
KBKrystof Bankiewicz
Krystof Bankiewicz
FMFahar Merchant
Fahar Merchant
Purpose: The current study compared the standard response assessment in neuro-oncology (RANO), immunotherapy RANO (iRANO), and modified RANO (mRANO) criteria as well as quantified the association between progression-free (PFS) and overall survival (OS) in an immunotherapy trial in recurrent glioblastoma (rGBM). Patients and Methods: A total of 47 patients with rGBM were enrolled in a prospective phase II convection-enhanced delivery of an IL4R-targeted immunotoxin (MDNA55-05, NCT02858895). Bidirectional tumor measurements were created by local sites and centrally by an independent radiologic faculty, then standard RANO, iRANO, and mRANO criteria were applied. Results: A total of 41 of 47 patients (mean age 56 ± 11.7) were evaluable for response. PFS was significantly shorter using standard RANO compared with iRANO (log-rank, P < 0.0001; HR = 0.3) and mRANO (P < 0.0001; HR = 0.3). In patients who died and had confirmed progression on standard RANO, no correlation was observed between PFS and OS (local, P = 0.47; central, P = 0.34). Using iRANO, a weak association was observed between confirmed PFS and OS via local site measurements (P = 0.017), but not central measurements (P = 0.18). A total of 24 of 41 patients (59%) were censored using iRANO and because they lacked confirmation of progression 3 months after initial progression. A strong correlation was observed between mRANO PFS and OS for both local (R2 = 0.66, P < 0.0001) and centrally determined reads (R2 = 0.57, P = 0.0007). Conclusions: No correlation between radiographic PFS and OS was observed for standard RANO or iRANO, but a correlation was observed between PFS and OS using the mRANO criteria. Also, the iRANO criteria was difficult to implement due to need to confirm progression 3 months after initial progression, censoring more than half the patients.